fda compounding semaglutide news november 2025 The has approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection, Wegovy HD, for weight loss and long-term weight maintenance in certain adult patients—in just 54 days from filing Hims & Hers stock falls

However, only a small number of patients were included in the study, and median levels were not elevated even before the commencement of GLP-1 RAs treatment (102)

Metabolic inefficiency

The drug is currently approved for additional uses, including reducing cardiovascular risks in people with type 2 diabetes and heart disease, and reducing the risk of kidney decline in people with type 2 diabetes and chronic kidney disease (CKD)

Your body does adjust

GLP-1 receptors exist on immune cells, not just in the pancreas or the gut

Body Composition Preservation: While older weight-loss methods stripped both fat and muscle, GLP-1 therapycombined with adequate protein and resistance exercise, preferentially preserves lean muscle mass, protecting your metabolic rate and functional capacity